An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Blood
Ravi VijDavid S Siegel

Abstract

Carfilzomib is a selective proteasome inhibitor that binds irreversibly to its target. In phase 1 studies, carfilzomib elicited promising responses and an acceptable toxicity profile in patients with relapsed and/or refractory multiple myeloma (R/R MM). In the present phase 2, multicenter, open-label study, 129 bortezomib-naive patients with R/R MM (median of 2 prior therapies) were separated into Cohort 1, scheduled to receive intravenous carfilzomib 20 mg/m(2) for all treatment cycles, and Cohort 2, scheduled to receive 20 mg/m(2) for cycle 1 and then 27 mg/m(2) for all subsequent cycles. The primary end point was an overall response rate (≥ partial response) of 42.4% in Cohort 1 and 52.2% in Cohort 2. The clinical benefit response (overall response rate + minimal response) was 59.3% and 64.2% in Cohorts 1 and 2, respectively. Median duration of response was 13.1 months and not reached, and median time to progression was 8.3 months and not reached, respectively. The most common treatment-emergent adverse events were fatigue (62.0%) and nausea (48.8%). Single-agent carfilzomib elicited a low incidence of peripheral neuropathy-17.1% overall (1 grade 3; no grade 4)-in these pretreated bortezomib-naive patients. The results of th...Continue Reading

References

Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Jul 10, 2007·Cancer Research·Susan D DemoMark K Bennett
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiJean-Luc Harousseau
Feb 6, 2008·Journal of Medicinal Chemistry·Bruce D DorseyJohn P Mallamo
Mar 4, 2009·Current Problems in Cancer·S Vincent Rajkumar
Apr 18, 2009·Molecular Aspects of Medicine·Tobias JungTilman Grune
Nov 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Owen A O'ConnorRobert Z Orlowski
Mar 23, 2010·Cancer Chemotherapy and Pharmacology·Donna E ReeceA Keith Stewart
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Mar 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shirin Arastu-KapurChristopher J Kirk
May 25, 2011·Journal of the National Cancer Institute·Amy M RuschakAaron D Schimmer
Oct 7, 2011·Journal of the National Comprehensive Cancer Network : JNCCN·Jacob P LaubachPaul G Richardson

❮ Previous
Next ❯

Citations

Nov 19, 2013·Annals of Hematology·Silvia ParkKihyun Kim
Aug 27, 2013·Cancer Chemotherapy and Pharmacology·Kyriakos P PapadopoulosJeffery R Infante
Apr 29, 2010·Current Hematologic Malignancy Reports·Jonathan KaufmanSagar Lonial
Oct 16, 2012·Current Hematologic Malignancy Reports·Panisinee LawasutPaul G Richardson
Oct 1, 2013·Current Hematologic Malignancy Reports·Tommasina Guglielmelli, Antonio Palumbo
Mar 10, 2010·Medical Oncology·Tiffany Richards, Donna Weber
Feb 20, 2010·Medical Oncology·Jacob P LaubachKenneth C Anderson
Feb 9, 2013·Blood·K Martin Kortuem, A Keith Stewart
Feb 7, 2013·Oman Medical Journal·Khalil Al-Farsi
Jan 3, 2014·The Journal of Clinical Investigation·Nathaniel M Weathington, Rama K Mallampalli
Mar 1, 2014·Nature Reviews. Drug Discovery·Matthias Dobbelstein, Ute Moll
Jun 27, 2014·BioMed Research International·Alessandra RomanoFrancesco Di Raimondo
Sep 13, 2014·Hematology/oncology Clinics of North America·Silvia Gentili, Sagar Lonial
Dec 18, 2013·Medicina clínica·Albert Oriol, Cristina Motlló
Oct 10, 2014·Continuum : Lifelong Learning in Neurology·Nathan P Staff, Anthony J Windebank
Oct 12, 2012·OncoTargets and Therapy·Karel FostierRik Schots
Mar 13, 2013·Expert Review of Anticancer Therapy·Ali McBride, Patricia Y Ryan
Dec 7, 2013·Expert Review of Anticancer Therapy·Chiara CerratoAntonio Palumbo
Dec 20, 2013·Expert Review of Hematology·Enrique M OcioKenneth C Anderson
May 28, 2013·Expert Opinion on Pharmacotherapy·Efstathios KastritisMeletios A Dimopoulos
Dec 30, 2014·Pharmaceuticals·Noah M Merin, Kevin R Kelly
Jun 7, 2014·Expert Opinion on Investigational Drugs·Sara BringhenAntonio Palumbo
Jun 19, 2013·Expert Opinion on Biological Therapy·Sonia Vallet, Klaus Podar
Jul 10, 2014·Expert Opinion on Drug Safety·Hui WangHuanjie Yang
Dec 17, 2014·Expert Opinion on Investigational Drugs·Jeffrey D Altenburg, Sherif S Farag
Aug 30, 2014·Expert Opinion on Biological Therapy·Claudia Andreu-Vieyra, James R Berenson
Jul 10, 2013·Expert Opinion on Drug Metabolism & Toxicology·Chiara PautassoAntonio Palumbo
Oct 19, 2013·Seminars in Oncology·María-Victoria MateosJesús F San Miguel
Apr 30, 2013·Blood Reviews·Antonio Palumbo, Roberto Mina
Nov 14, 2015·American Journal of Hematology·S Vincent Rajkumar
Jul 29, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosJ San-Miguel
Feb 7, 2015·Journal of Medicinal Chemistry·Zachary MillerKyung Bo Kim

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.